Mirvie RNA test aims to predict pregnancy complications

Gameto’s Fertilo gets FDA clearance for a phase 3 trial, pioneering iPSC-based fertility treatment to shorten IVF cycles and improve reproductive care.

In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.

A recent study found insufficient evidence that oral furosemide reduces the risk of de novo postpartum hypertension, highlighting the need for close monitoring in the first 2 weeks after birth.

In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.

Vvax001, a new HPV16 vaccine, offers a potential alternative to surgery for treating precancerous cervical lesions, with promising trial results.

A recent study highlights lasting platelet hyperreactivity in women with gestational diabetes mellitus, suggesting it could serve as a therapeutic target to mitigate long-term complications.